GlassScriptPhysician profile
Alnoor A Malick
NPI 1780689679
$8,505.43
in general payments reported to CMS, 2019-2025
35 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $305 · 2021: $2,329 · 2022: $759 · 2023: $1,602 · 2024: $1,237 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,239 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,239.35 |
| Education | $155.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,954.46 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,162.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $805.11 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $489.46 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $405.32 | 2019-2025 | |
| Pfizer INC. | $394.87 | 2019-2025 | |
| Grifols USA, LLC | $299.55 | 2019-2025 | Xembify |
| Genzyme Corporation | $289.57 | 2019-2025 | |
| Csl Behring | $271.57 | 2019-2025 | Hizentra, Andembry |
| Blueprint Medicines Corporation | $260.08 | 2021-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $233.64 | 2021-2023 | Orladeyo |
| Amgen INC. | $224.45 | 2021-2025 | Tezspire |
| Optinose US, INC. | $212.35 | 2019-2025 | |
| Kaleo, INC. | $210.35 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $206.34 | 2019-2023 | Grastek, Odactra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.30 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $150.24 | 2025 | Neffy |
| Leo Pharma INC. | $123.76 | 2022-2024 | Adbry |
| Shire North American Group INC | $121.44 | 2019 | |
| Octapharma USA, INC. | $112.21 | 2019-2023 | Cutaquig |
| Hospira, INC. | $69.15 | 2024-2025 | |
| Organon LLC | $47.50 | 2025 | Vtama |
| Azurity Pharmaceuticals, INC. | $42.64 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $39.96 | 2025 | Dawnzera |
| Galderma Laboratories, L.P. | $32.85 | 2025 | Nemluvio |
| Incyte Corporation | $28.29 | 2024 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $22.25 | 2021 | |
| Mdd US Operations, LLC | $19.49 | 2020 | |
| Hikma Pharmaceuticals USA | $17.85 | 2024 | Ryaltris |
| Sunovion Pharmaceuticals INC. | $17.67 | 2019 | |
| Covis Pharma Gmbh | $16.93 | 2023 | |
| Aimmune Therapeutics, INC. | $15.53 | 2022 | |
| Tersera Therapeutics LLC | $15.21 | 2023 | Quzyttir |
| Uswm, LLC | $14.00 | 2021 | |
| Horizon Therapeutics Plc | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alnoor Malick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.